Skip to Content

Study with 3,334 patients validates circulating tumor DNA for genomic sequencing as an alternative to biopsies in mCRPC

The study demonstrated a high correlation between gene mutation changes identified by circulating tumor DNA (ctDNA) and biopsy-based genomic sequencing. In addition, liquid biopsies were better at identifying acquired resistance mechanisms than tissue biopsies.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top